Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 28, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10:40 a.m. ET.
The webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
